Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Early Detection of Diabetic Peripheral Neuropathy and its Importance

Magnifying glass above a table full of papers featuring runes.

A newly published article critically appraises research and clinical methods for the diagnosis or screening of early DPN. In brief, functional measures are subjective and are difficult to implement due to technical complexity. Moreover, skin biopsy is invasive, expensive and lacks diagnostic laboratory capacity. Indeed, point-of-care nerve conduction tests are convenient and easy to implement however questions are raised regarding their suitability for use in screening due to the lack of small nerve fibre evaluation.

The signs and symptoms of DPN are insidious and current screening programmes rely on subjective tests of large nerve fibre dysfunction. NICE recommends vibration perception testing using a 128 Hz tuning fork together with a 10 g (Semmes-Weinstein) monofilament for the screening of DPN. However, these tests identify DPN at a late, irreversible, pre-ulcerative stage. Thus, an abnormal monofilament test is associated with a 3-year relative risk of 15% (95% CI 9.0 to 26.0) for foot ulceration or lower limb amputation. Despite, early and progressive injury to small fibres in diabetes, small nerve fibre assessment is not included in annual diabetic foot screening programmes.

‘Despite the higher sensitivity, the lower specificity of Neuropad compared to the 10 g monofilament and lower cost-effectiveness led NICE as part of the Medical Technologies Evaluation and Diagnostics Assessment Programme to not approve its use as a DPN screening test. We believe
this decision is short sighted as the specificity of any test which detects disease earlier is bound to be lower.’

Read the full report.